Search research articles
Contact Us
Filters
Showing results (11-20 of 30) with videos related to
Page
of 3
Sort By:
Scientific Reports
|
January 25, 2018
Capturing expert uncertainty in spatial cumulative impact assessments
Alice R Jones, Zoë A Doubleday, Thomas A A Prowse, et al.
The American Journal of Pathology
|
July 25, 2009
Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy
Jian-Mei Hou, Alastair Greystoke, Lee Lancashire, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
December 17, 2016
Optimal design and patient selection for interventional trials using radiogenomic biomarkers: A REQUITE and Radiogenomics consortium statement
Dirk De Ruysscher, Gilles Defraene, Bram L T Ramaekers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 19, 2012
Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer
Jian-Mei Hou, Matthew G Krebs, Lee Lancashire, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 25, 2009
Phase I trial of AEG35156 administered as a 7-day and 3-day continuous intravenous infusion in patients with advanced refractory cancer
Emma Dean, Duncan Jodrell, Kate Connolly, et al.
Clinical and Translational Radiation Oncology
|
February 24, 2026
PACE-NODES: A phase III randomised trial of 5 fraction prostate stereotactic body radiotherapy (SBRT) versus 5 fraction prostate and pelvic nodal SBRT
Angela Pathmanathan, Suneil Jain, John Staffurth, et al.
Frontiers in Oncology
|
May 13, 2017
Data-Based Radiation Oncology: Design of Clinical Trials in the Toxicity Biomarkers Era
David Azria, Ariane Lapierre, Sophie Gourgou, et al.
Journal of the National Cancer Institute
|
October 3, 2002
Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies
Gordon C Jayson, Jamal Zweit, Alan Jackson, et al.
Magnetic Resonance in Medicine
|
June 27, 2013
Noninvasive tumor hypoxia measurement using magnetic resonance imaging in murine U87 glioma xenografts and in patients with glioblastoma
Inna V Linnik, Marietta L J Scott, Katherine F Holliday, et al.
International Journal of Cancer
|
November 1, 2023
Reply to: Comments on "(Pre)treatment risk factors for late fatigue and fatigue trajectories following radiotherapy for breast cancer"
Juan C Rosas, Miguel E Aguado-Barrera, David Azria, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 30) with videos related to
Sort By:
Page
of 3
Scientific Reports
|
January 25, 2018
Capturing expert uncertainty in spatial cumulative impact assessments
Alice R Jones, Zoë A Doubleday, Thomas A A Prowse, et al.
The American Journal of Pathology
|
July 25, 2009
Evaluation of circulating tumor cells and serological cell death biomarkers in small cell lung cancer patients undergoing chemotherapy
Jian-Mei Hou, Alastair Greystoke, Lee Lancashire, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology
|
December 17, 2016
Optimal design and patient selection for interventional trials using radiogenomic biomarkers: A REQUITE and Radiogenomics consortium statement
Dirk De Ruysscher, Gilles Defraene, Bram L T Ramaekers, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 19, 2012
Clinical significance and molecular characteristics of circulating tumor cells and circulating tumor microemboli in patients with small-cell lung cancer
Jian-Mei Hou, Matthew G Krebs, Lee Lancashire, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 25, 2009
Phase I trial of AEG35156 administered as a 7-day and 3-day continuous intravenous infusion in patients with advanced refractory cancer
Emma Dean, Duncan Jodrell, Kate Connolly, et al.
Clinical and Translational Radiation Oncology
|
February 24, 2026
PACE-NODES: A phase III randomised trial of 5 fraction prostate stereotactic body radiotherapy (SBRT) versus 5 fraction prostate and pelvic nodal SBRT
Angela Pathmanathan, Suneil Jain, John Staffurth, et al.
Frontiers in Oncology
|
May 13, 2017
Data-Based Radiation Oncology: Design of Clinical Trials in the Toxicity Biomarkers Era
David Azria, Ariane Lapierre, Sophie Gourgou, et al.
Journal of the National Cancer Institute
|
October 3, 2002
Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies
Gordon C Jayson, Jamal Zweit, Alan Jackson, et al.
Magnetic Resonance in Medicine
|
June 27, 2013
Noninvasive tumor hypoxia measurement using magnetic resonance imaging in murine U87 glioma xenografts and in patients with glioblastoma
Inna V Linnik, Marietta L J Scott, Katherine F Holliday, et al.
International Journal of Cancer
|
November 1, 2023
Reply to: Comments on "(Pre)treatment risk factors for late fatigue and fatigue trajectories following radiotherapy for breast cancer"
Juan C Rosas, Miguel E Aguado-Barrera, David Azria, et al.
Page
of 3